Last updated: February 19, 2026
This report analyzes World Intellectual Property Organization (WIPO) patent application WO2019191353, titled "N-ALKYLAMINOMETHYLIDENE GUANIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF THE IMMUNE SYSTEM." The patent application concerns novel guanidine derivatives and their therapeutic applications, primarily as immune system modulators. The analysis details the invention's core technological aspects, the breadth of its claims, and its positioning within the existing pharmaceutical patent landscape, focusing on implications for research and development investment.
What is the Core Invention of WO2019191353?
The invention described in WO2019191353 centers on a class of chemical compounds classified as N-alkylaminomethylene guanidine derivatives. These compounds are presented as having the ability to modulate the immune system. The application specifies a general chemical structure and provides numerous examples of specific compounds falling within this class. The primary intended use for these compounds is the treatment of diseases and conditions where immune system modulation is beneficial.
The patent application details the synthesis of these compounds and provides in vitro and in vivo data to support their biological activity. The biological targets and mechanisms of action are broadly described, focusing on their immunomodulatory properties. This includes their potential to either stimulate or suppress immune responses, depending on the specific compound and therapeutic context.
What are the Key Claims of WO2019191353?
The claims of WO2019191353 define the legal scope of the invention. These claims are structured hierarchically, with independent claims setting the broadest scope and dependent claims providing narrower, more specific protections.
Independent Claims:
- Claim 1: This claim broadly covers N-alkylaminomethylene guanidine derivatives of Formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof. Formula (I) is defined by specific substituent groups (R1, R2, R3, R4, R5, R6, X, Y, Z) which, when varied, define the scope of the chemical space claimed. For example, R1 can be a hydrogen atom, an alkyl group, or a substituted alkyl group. R2 can be a substituted or unsubstituted aromatic or heteroaromatic ring. The substituents and their possible variations are extensive, defining a large family of chemical entities.
- Claim 11: This independent claim concerns a pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier. This claim covers the formulation of the active ingredients into a usable drug product.
- Claim 13: This independent claim relates to the use of a compound according to claim 1 for the manufacture of a medicament. This claim covers the application of the claimed compounds in treating specific diseases.
Dependent Claims:
The dependent claims narrow the scope of the independent claims by imposing specific limitations on the substituents defined in Formula (I). Examples of such limitations include:
- Defining specific ranges for the number of carbon atoms in alkyl groups (e.g., R1 is an alkyl group having from 1 to 6 carbon atoms).
- Specifying particular examples of aromatic or heteroaromatic rings for R2 (e.g., R2 is a phenyl group or a pyridyl group).
- Restricting the nature of linker groups X, Y, and Z.
- Further defining specific compounds by explicitly referencing them in the examples.
These dependent claims serve to provide fallback positions in case the broader claims are challenged and to offer more focused protection for specific embodiments of the invention. The precise definitions of the substituents and their permissible variations are critical for determining the exact scope of protection afforded by the patent.
What is the Technological Scope of the Invention?
The technological scope of WO2019191353 encompasses the synthesis, characterization, and therapeutic application of a novel class of N-alkylaminomethylene guanidine derivatives.
Chemical Synthesis: The application provides detailed procedures for synthesizing the claimed compounds, including reaction schemes, reagents, and conditions. This indicates that the invention includes not only the compounds themselves but also the methods by which they can be manufactured.
Biological Activity: The core technological contribution lies in the demonstrated immunomodulatory activity of these compounds. This activity is explored in the context of various disease indications. Specific examples provided in the patent application illustrate the compounds' effects on biological pathways relevant to immune responses. The data presented is typically in vitro, measuring cellular responses, or in vivo, using animal models to assess efficacy and safety.
Therapeutic Applications: The claimed therapeutic applications are broad, covering a range of conditions influenced by immune system function. This includes, but is not limited to, inflammatory diseases, autoimmune disorders, infectious diseases, and cancer. The patent application suggests that the compounds can be used to either enhance or dampen immune responses, offering a versatile platform for therapeutic development.
What is the Patent Landscape for Immunomodulatory Guanidine Derivatives?
The patent landscape for immunomodulatory guanidine derivatives is complex and competitive, with numerous entities actively pursuing intellectual property in this area. WO2019191353 fits within this broader landscape, but its specific chemical structure and claimed applications differentiate it.
Key Players and Trends:
- Major Pharmaceutical Companies: Large pharmaceutical firms hold significant portfolios of patents related to immunomodulatory agents, including those with guanidine-like structures. These companies often focus on broad claims covering entire chemical classes and diverse therapeutic applications.
- Biotechnology Companies: Smaller biotech firms and academic institutions are also active, often patenting more specific compounds or novel mechanisms of action. Their patent strategies may focus on niche indications or specific therapeutic targets.
- Emerging Chemical Space: The landscape shows a continuous drive to discover novel chemical scaffolds with improved efficacy, safety, and pharmacokinetic profiles compared to existing immunomodulators. Guanidine derivatives represent one avenue of exploration.
- Focus on Specific Immune Pathways: Recent patent filings increasingly demonstrate a trend towards targeting specific components of the immune system, such as particular cytokines, receptors, or cell types. This allows for more precise therapeutic interventions.
Competitive Considerations for WO2019191353:
- Prior Art: The novelty and inventiveness of WO2019191353 will be assessed against existing patents and publications describing similar guanidine derivatives or compounds with similar immunomodulatory activities. The breadth of the claims will be crucial here.
- Existing Marketed Drugs: A significant number of immunomodulatory drugs are already on the market, targeting a wide array of diseases. The patent landscape is shaped by the need to offer differentiated therapeutic benefits or target unmet medical needs.
- Freedom to Operate: Companies seeking to develop compounds within the scope of WO2019191353 would need to conduct thorough freedom-to-operate analyses to ensure their activities do not infringe on existing patents, including WO2019191353 itself if granted.
Key Patent Families and Technologies:
While a comprehensive landscape analysis requires dedicated patent searching, typical prior art in this domain might include patents covering:
- Other classes of small molecule immunomodulators (e.g., JAK inhibitors, BTK inhibitors).
- Monoclonal antibodies targeting immune checkpoints or cytokines.
- Gene therapies and cell-based immunotherapies.
- Earlier guanidine derivatives with different substitution patterns or purported biological activities.
The granted claims of WO2019191353, if it proceeds to grant, will define its specific position and the potential constraints it places on competitors in the immunomodulatory drug development space.
What are the Potential Therapeutic Indications?
The patent application for WO2019191353 outlines a broad spectrum of potential therapeutic indications for the claimed N-alkylaminomethylene guanidine derivatives, all stemming from their immunomodulatory properties.
Inflammatory and Autoimmune Diseases:
- Rheumatoid Arthritis: Conditions characterized by chronic inflammation of the joints.
- Psoriasis: A chronic autoimmune disease causing raised, red, scaly patches on the skin.
- Inflammatory Bowel Disease (IBD): Including Crohn's disease and ulcerative colitis.
- Multiple Sclerosis (MS): A chronic disease in which the immune system attacks the protective sheath that covers nerve fibers, causing communication problems between the brain and the rest of the body.
- Lupus Erythematosus: An autoimmune disease that can affect skin, joints, kidneys, brain cells, and other organs.
Infectious Diseases:
- The compounds may be used to modulate the immune response to pathogens, potentially enhancing the body's ability to clear infections or mitigating harmful inflammatory responses associated with infection.
Oncology:
- Cancer Immunotherapy: The compounds could be employed to stimulate the immune system to recognize and attack cancer cells, either as monotherapy or in combination with other cancer treatments. This could involve enhancing anti-tumor immunity or overcoming immune suppression in the tumor microenvironment.
Other Conditions:
- The general immunomodulatory nature of the compounds suggests potential utility in other conditions where dysregulated immune responses play a role, such as transplant rejection or certain allergic disorders.
The specific therapeutic utility would depend on whether the compounds are designed to enhance or suppress immune activity and the precise pathways they modulate. The broad claims suggest a versatile platform for addressing a wide range of immunological dysfunctions.
How is the Invention Protected?
The invention described in WO2019191353 is protected by its claims, which define the exclusive rights granted to the applicant. These rights typically prevent others from making, using, selling, offering for sale, or importing the claimed subject matter without authorization for the duration of the patent.
Key Aspects of Protection:
- Composition of Matter Claims: The primary protection comes from composition of matter claims (e.g., Claim 1), which cover the novel chemical compounds themselves. If granted, this is the strongest form of patent protection, as it covers the compound regardless of its specific use or manufacturing method.
- Pharmaceutical Composition Claims: Claim 11 protects specific formulations of the claimed compounds, ensuring that even if a competitor synthesizes the compound, they cannot legally market a drug product containing it without a license.
- Method of Use Claims: Claim 13 and dependent claims related to therapeutic uses protect the application of the compounds for treating specific diseases. These claims are crucial for defining the commercial market for the invention.
- Geographic Coverage: WIPO patent applications, once published, facilitate the filing of national or regional patent applications in designated countries. The extent of protection will ultimately depend on where patents are granted and the specific claims allowed in each jurisdiction.
- Patent Term: The term of a patent is typically 20 years from the filing date, subject to the payment of maintenance fees. This provides a period of market exclusivity for the innovators.
Potential Challenges and Limitations:
- Novelty and Inventive Step: The patentability of WO2019191353 will depend on demonstrating that the claimed compounds are novel and involve an inventive step over the existing prior art.
- Enablement and Written Description: The patent application must adequately describe the invention to enable a person skilled in the art to make and use it, and it must provide a written description that supports the full scope of the claims.
- Infringement Analysis: Competitors will likely design around the claims. Any entity developing similar compounds would need to conduct careful freedom-to-operate analysis to avoid infringement.
- Enforcement: Protecting patent rights requires active monitoring and, if necessary, legal enforcement against infringers.
The granted patent will establish a defined territory of exclusivity for the claimed guanidine derivatives, impacting competitive activity in the immunomodulatory drug development sector.
Key Takeaways
WO2019191353 seeks to protect a novel class of N-alkylaminomethylene guanidine derivatives for their immunomodulatory properties. The application's independent claims cover the chemical compounds, pharmaceutical compositions, and their use in manufacturing medicaments for various therapeutic indications, including inflammatory, autoimmune, infectious, and oncological diseases. The patent landscape for immunomodulators is competitive, with significant activity from major pharmaceutical and biotechnology companies. The strength and scope of protection afforded by WO2019191353, if granted, will hinge on its claims' novelty and inventiveness relative to prior art and will impact the freedom to operate for competitors developing similar agents.
FAQs
-
What specific chemical structure defines the compounds claimed in WO2019191353?
The compounds are defined by Formula (I), which specifies an N-alkylaminomethylene guanidine core with various substituent groups (R1 through R6, X, Y, Z) that can be varied within defined ranges and types.
-
Does WO2019191353 claim specific therapeutic uses, or is it focused solely on the chemical compounds?
The application includes both composition of matter claims for the chemical compounds and method of use claims for their application in manufacturing medicaments for treating specific disease categories, such as inflammatory, autoimmune, infectious, and oncological conditions.
-
How does WO2019191353 differentiate itself from existing immunomodulatory drugs or patents?
Differentiation would stem from the unique chemical structure of the N-alkylaminomethylene guanidine derivatives and their specific, empirically demonstrated immunomodulatory profile and associated therapeutic benefits, as detailed in the application's data and claims.
-
What is the current status of WO2019191353 (application or granted patent)?
WO2019191353 is a WIPO PCT application, meaning it has been published. Its progression to a granted patent will depend on national or regional examination procedures in countries where patent protection is sought.
-
What are the implications for a company looking to develop a new immunomodulator if WO2019191353 is granted?
If granted with broad claims, WO2019191353 could restrict competitors from developing or commercializing compounds falling within its defined chemical space or for the claimed therapeutic uses without a license. A thorough freedom-to-operate analysis would be essential.
Citations
[1] World Intellectual Property Organization. (2019). N-ALKYLAMINOMETHYLIDENE GUANIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF THE IMMUNE SYSTEM. PCT Application WO2019191353A1.
